Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC).
Fine JS, Ambrose AF, Didehbani N, Fleming TK, Glashan L, Longo M, Merlino A, Ng R, Nora GJ, Rolin S, Silver JK, Terzic CM, Verduzco-Gutierrez M, Sampsel S. Fine JS, et al. PM R. 2022 Jan;14(1):96-111. doi: 10.1002/pmrj.12745. Epub 2022 Jan 12. PM R. 2022. PMID: 34902226 No abstract available.
Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of neurologic sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC).
Melamed E, Rydberg L, Ambrose AF, Bhavaraju-Sanka R, Fine JS, Fleming TK, Herman E, Phipps Johnson JL, Kucera JR, Longo M, Niehaus W, Oleson CV, Sampsel S, Silver JK, Smith MM, Verduzco-Gutierrez M. Melamed E, et al. Among authors: fine js. PM R. 2023 May;15(5):640-662. doi: 10.1002/pmrj.12976. Epub 2023 May 9. PM R. 2023. PMID: 36989078 No abstract available.
Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of mental health symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC).
Cheng AL, Anderson J, Didehbani N, Fine JS, Fleming TK, Karnik R, Longo M, Ng R, Re'em Y, Sampsel S, Shulman J, Silver JK, Twaite J, Verduzco-Gutierrez M, Kurylo M. Cheng AL, et al. Among authors: fine js. PM R. 2023 Dec;15(12):1588-1604. doi: 10.1002/pmrj.13085. Epub 2023 Nov 8. PM R. 2023. PMID: 37937672 No abstract available.
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative.
Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, Baizer L, Goldman JD, Rouphael N, Deitchman A, Fine J, Fontelo P, Kim AY, Shaw G, Stratford J, Ceger P, Costantine MM, Fisher L, O'Brien L, Maughan C, Quigley JG, Gabbay V, Mohandas S, Williams D, McComsey GA. Bonilla H, et al. Front Immunol. 2023 Mar 9;14:1129459. doi: 10.3389/fimmu.2023.1129459. eCollection 2023. Front Immunol. 2023. PMID: 36969241 Free PMC article. Review.
Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells.
White D, Cote-Martin A, Bleck M, Garaffa N, Shaaban A, Wu H, Liu D, Young D, Scheer J, Lorenz IC, Nixon A, Fine JS, Byrne FR, Mbow ML, Moreno-Garcia ME. White D, et al. Among authors: fine js. Mol Immunol. 2023 Apr;156:31-38. doi: 10.1016/j.molimm.2023.02.007. Epub 2023 Mar 6. Mol Immunol. 2023. PMID: 36889184
105 results